Medical supplies group QT Vascular and its chief executive officer, Eitan Konstantino, have successfully defended themselves against a patent infringement lawsuit filed by another medical company AngioScore, the company said in a Singapore Exchange filing on Wednesday.
This means that QT Vascular can continue to sell its "Chocolate PTA" balloon catheter without impediment, the Catalist-listed group said in its statement.
It said that after a seven-day trial in California, the jury decided that QT Vascular's Chocolate PTA does not infringe the patent in question.
AngioScore, a specialty balloon angioplasty firm that was co-founded by Dr Konstantino, had claimed that Chocolate PTA infringed the '119 Patent - a patent that claims a very specific design for an angioplasty balloon catheter and a non-deployable stent.
However, QT Vascular said on Wednesday that the jury's unanimous verdict "confirms that Chocolate is substantially different from the design disclosed in the '119 patent".
Based on the verdict, the group does not expect to incur any liability on the patent claim, it said.